Jeffrey Cranmer

Looking for that special something to give your favorite @packers fan? Push here. #FlyEaglesFly https://t.co/sGjw4CvFvQ

The biggest licensing deal yet for a China biotech asset -- @Pfizer taking rights to a 3SBio bispecific -- is also tied for 3rd largest biotech asset deal ever. The deal for a PD-(L)1 x VEGF has $PFE paying $1.25B u/f Here's @BioBonanos in @biocentury https://t.co/7GAgLSDCdA

RT @steveusdin1: FDA misses PDUFA goal for Stealth’s Barth syndrome treatment It isn’t clear whether staffing cuts or loss of FDA champion…

Another missed deadline by RFK Jr. & Makary's @US_FDA -- this time for a treatment for a very rare disease: https://t.co/tHDE9geBED

Krause, @llborio on turmoil @US_FDA: "Moving the goalposts like this has a chilling effect on the entire biotech community and reduces appetite to develop critically needed new drugs and biologics in areas beyond just vaccines, including immunotherapies and cancer treatments."

steve usdin @steveusdin1

To safeguard sound decision-making at FDA, political interference must be kept out of product reviews, argue Phil Krause and Luciana Borio (@llborio) in a BioCentury Guest Commentary https://t.co/5VbSBSDyWX

RT @steveusdin1: The leaked Trump administration 2026 HHS budget is sickening. If enacted, it will destroy American science. NIH budget sla…

RT @KevinH_PhD: After 21 years at my dream job, I’m very sad to announce my early retirement from the National Institutes of Health. My lif…

RT @PHLEaglesNation: Go Birds, @EmmittSmith22.

Makary filling key @US_FDA spots with Capitol Hill alum Grace Graham, Washington lawyer Lowell Zeta, @BioCentury's @steveusdin1 has learned. They'll join the agency's Office of the Commissioner

Shanghai ADC play Duality braved one of HK's worst downturns of past 20 yrs to stick its landing on the HKSE, offering hope to China biotechs that have been suffering through a multiyear financing drought. I took a closer look in today's @BioCentury : https://t.co/QjXnFDw2Xv

Small molecule #Alzheimer's tx hits Ph 3 setback at #ADPD2025, but study's PIs argue for a subgroup effect in early-stage patients and a new surrogate endpoint -- hippocampal volume. My @BioCentury colleague @SelinaMKoch reports on the data as presented in Vienna at @adpdnet

"Not exactly a pick-me-up" says my @BioCentury pal @BioPharmaJosh about the new #BioCenturyThisWeek biotech podcast! But trust him, it's the stuff you need to know about what's happening to @US_FDA & $XBI. w/@steveusdin1 @FishburnSimone @StephenPHansen https://t.co/kApqNAoe54